Yongzhang LUO     Ph.D.

Professor


1981-1985, B.S., Department of Chemistry, Lanzhou University

1989-1993, Ph.D., Department of Molecular and Cell Biology, University of California at Berkeley

1993-1994, Postdoc., Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School

1994-1998, Postdoc., Department of Biochemistry, Stanford University School of Medicine


Dr. Luo is currently a professor at the School of Life Sciences, Tsinghua University, and the director of the National Engineering Research Center for Protein Technology.

 

Research interest


Our lab provides a comprehensive platform spanning from basic scientific discovery to the industrial translation of high-quality recombinant protein drugs. We are committed to resolving bottlenecks in the prevention and treatment of major diseases by deciphering the fundamental logic of life.


Our research areas mainly include the following aspects:

1. Mechanisms of Aging and Anti-aging

Exploring the core pathways and systemic interventions for maintaining health span from the perspective of the fundamental logic of life.

2. Mechanisms of Neurodegenerative Diseases

Focusing on the mechanistic research and clinical trial exploration of Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).

3. Mechanisms of Metabolic and Related Diseases

Investigating the pathogenic mechanisms and clinical translation of type 2 diabetes, obesity, and lipid metabolism (featuring the original discovery of the “Albumosome”), as well as muscle atrophy and repair, osteoporosis, and rheumatoid arthritis, from a comprehensive metabolic perspective.

4. Mechanisms of Cardiovascular Diseases

Investigating the pathogenic mechanisms and clinical translation of myocardial hypertrophy, cardiac fibrosis, and atrial fibrillation.

 

Selected publications


1. Ma B, Ju A, Zhang S, An Q, Xu S, Liu J, Yu L, Fu Y & Luo Y*. Albumosomes formed by pre-folding albumin in cytoplasm of hepatocytes maintain mitochondrial homeostasis and inhibit nonalcoholic fatty liver disease.

Signal Transduct Target Ther. 2023;8(1):229.doi: 10.1038/s41392-023-01437-0.

2. Liu, H., Ju, A., Dong, X. et al. Young and undamaged recombinant albumin alleviates T2DM by improving hepatic glycolysis through EGFR and protecting islet β cells in mice. J Transl Med 21, 89 (2023). https://doi.org/10.1186/s12967-023-03957-3

3. Tang J, Ju A, Li B, et al. Young and Undamaged rMSA Improves the Healthspan and Lifespan of Mice. Biomolecules. 2021;11(8):1191. doi:10.3390/biom11081191

4. Liu W, Li J, Zhang P, et al. A novel pan-cancer biomarker plasma heat shock protein 90alpha and its diagnosis determinants in clinic. Cancer Sci. 2019;110(9):2941-2959. doi:10.1111/cas.14143

5. Fu Y, Xu X, Huang D, et al. Plasma Heat Shock Protein 90alpha as a Biomarker for the Diagnosis of Liver Cancer: An Official, Large-scale, and Multicenter Clinical Trial. EBioMedicine. 2017;24:56-63. doi:10.1016/j.ebiom.2017.09.007

6. Wang H, Chen Y, Lu XA, Liu G, Fu Y, Luo Y. Endostatin Prevents Dietary-Induced Obesity by Inhibiting Adipogenesis and Angiogenesis. Diabetes. 2015;64(7):2442-2456. doi:10.2337/db14-0528

7. Wang X, Song X, Zhuo W, et al. The regulatory mechanism of Hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A. 2009;106(50):21288-21293. doi:10.1073/pnas.0908151106

8. Huang Y, Song N, Ding Y, et al. Pulmonary vascular destabilization in the premetastatic phase facilitates lung metastasis. Cancer Res. 2009;69(19):7529-7537. doi:10.1158/0008-5472.CAN-08-4382. “This landmark study demonstrated that ANGPT2-, MMP3- and MMP10-dependent pulmonary vascular destabilization is an early event occurring during the pre-metastatic phase, which promotes the extravasation of tumour cells and facilitates lung metastasis.” Cited and commented by Peinado, H., Zhang, H., Matei, I. et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17, 302–317 (2017). https://doi.org/10.1038/nrc.2017.6

9. Shi H, Huang Y, Zhou H, et al. Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin. Blood. (Featured in Cover) 2007;110(8):2899-2906. doi:10.1182/blood-2007-01-064428 Comment on Shi et al, page 2899, by Judah Folkman (2007). “Endostatin finds a new partner: nucleolin” Blood. 110, 2786-2787


Contact information


Tel:+86-10-62795106

Fax:+86-10-62794691

E-mail: protein@tsinghua.edu.cn